Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 57Genitourinary 35Breast 27Gastrointestinal 25Dermatologic 11Lymphoid 10Gynecologic 10Head & Neck 6Other solid neoplasm 5Other hematologic neoplasm 5CNS 5Tumor-Agnostic 4Sarcoma 2Plasma cell 1NET 1Endocrine 1

Conditions

Neoplasms 2Neoplasms, Unknown Primary 1Carcinoma 1

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × atezolizumab × Tumor-Agnostic × Clear all
NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed
529 enrolled 16 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT03637764 2023-07-10

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Sanofi

Phase 1/2 Terminated
107 enrolled 30 charts
Tumor-Agnostic

Neoplasms

NCT02367781 2021-08-09

IMpower130

Hoffmann-La Roche

Phase 3 Completed
723 enrolled 28 charts 1 FDA
Tumor-Agnostic

Carcinoma

NCT02458638 2021-06-04

A Study of Atezolizumab in Advanced Solid Tumors

Hoffmann-La Roche

Phase 2 Completed
474 enrolled 14 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡